

Carlo Buonerba

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3260462/carlo-buonerba-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

2,784
citations

29
h-index

46
g-index

159
ext. papers

3,488
ext. citations

4.2
avg, IF

4.81
L-index

#	Paper	IF	Citations
131	Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. <i>Nutrients</i> , 2021 , 13,	6.7	8
130	Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	22
129	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021 , 13,	6.6	1
128	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 651745	5.3	4
127	Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study. <i>Future Science OA</i> , 2021 , 7, FSO745	2.7	0
126	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. <i>Urologia Internationalis</i> , 2021 , 1-8	1.9	2
125	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
124	Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study. <i>Future Science OA</i> , 2021 , 7, FSO643	2.7	4
123	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021 , 17, 3987-3994	3.6	2
122	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 6930	2.6	1
121	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. <i>Future Science OA</i> , 2021 , 7, FSO709	2.7	8
120	Development of a municipality index of environmental pressure in Campania, Italy. <i>Future Science OA</i> , 2021 , 7, FSO720	2.7	2
119	Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer. <i>Future Science OA</i> , 2021 , 7, FSO719	2.7	0
118	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. <i>Minerva Urology and Nephrology</i> , 2021 , 73, 442-451	2.3	7
117	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
116	Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review. <i>Cancers</i> , 2020 , 12,	6.6	4
115	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 459-464	2.8	26

114	Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review. <i>OncoTargets and Therapy</i> , 2020 , 13, 1179-1184	4.4	1
113	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	19
112	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020 , 11, 2083-2091	3.3	5
111	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
110	Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020 , 10, 1556	5.3	3
109	The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department. <i>Future Science OA</i> , 2020 , 7, FSO635	2.7	2
108	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
107	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	12
106	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 377-387	3.8	28
105	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019 , 79, 381-400	12.1	15
104	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1400	5.3	21
103	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019 , 37, 1049-1059	4	4
102	Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 56-62	0.7	4
101	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
100	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018 , 9, 189	5.6	12
99	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
98	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. <i>Medicine (United States)</i> , 2018 , 97, e11254	1.8	7
97	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018 , 9, 4250-4254	4.5	18

96	Serum and tissue markers in colorectal cancer: State of art. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 103-116	7	19
95	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017 , 13, 1338-1342	4	
94	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
93	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 461.e15-461.e27	2.8	45
92	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
91	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017 , 13, 285-293	3.6	37
90	The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2017 , 8, 788	5.6	2
89	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017 , 8, 18424-18434	3.3	44
88	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017 , 8, 104654-104663	3.3	36
87	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16503-e16503	2.2	
86	A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review. <i>Medicine (United States)</i> , 2016 , 95, e3642	1.8	4
85	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016 , 12, 399-411	3.6	27
84	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
83	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2	
82	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
81	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016 , 4, 100	3.2	16
80	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report. <i>Medicine (United States)</i> , 2016 , 95, e2598	1.8	12
79	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. <i>Medicine (United States)</i> , 2016 , 95, e2754	1.8	2

78	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 494-498	3.3	1
77	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9
76	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
75	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1113-1120	3.8	5
74	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
73	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 236-9	2.4	6
72	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
71	The use of interferon in melanoma patients: a systematic review. <i>Cytokine and Growth Factor Reviews</i> , 2015 , 26, 203-12	17.9	43
70	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
69	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
68	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. <i>OncoTargets and Therapy</i> , 2015 , 8, 1345-9	4.4	4
67	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015 , 94, e2117	1.8	34
66	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 534-41	7	27
65	Correlative Imaging in a Patient with Cystic Thymoma: CT, MR and PET/CT Comparison. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2015 , 80, 22-6		9
64	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015 , 10, e0139696	3.7	29
63	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 335-335	2.2	
62	Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 225-225	2.2	
61	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21

60	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014 , 10, 2141-7	3.6	21
59	Metastasis to the kidney from a B2 thymoma: report of a case. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 656-8	1.2	
58	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S81-7	8.9	71
57	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S65-72	8.9	243
56	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S73-80	8.9	92
55	Poor survival in prostate cancer patients with primary refractoriness to docetaxel. <i>European Urology</i> , 2014 , 65, 505-7	10.2	17
54	Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7528-7528	2.2	2
53	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014 , 2, 228-31	1.6	15
52	Optimal management of a patient with recurrent nasopharyngeal carcinoma. <i>World Journal of Clinical Cases</i> , 2014 , 2, 297-300	1.6	8
51	A case series of low-dose sorafenib plus tamoxifen in sorafenib-pretreated patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15139-e15139	2.2	
50	Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. <i>European Urology</i> , 2013 , 63, 961	10.2	3
49	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
48	Hypercastration in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 303-305	4.1	1
47	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
46	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 761-5	2.8	14
45	Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. <i>Anti-Cancer Drugs</i> , 2013 , 24, 759-64	2.4	4
44	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 857-9	6.4	2
43	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27

42	Penile cancer: current therapy and future directions. <i>Annals of Oncology</i> , 2013 , 24, 1179-89	10.3	61
41	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
40	Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 47-51	2.5	11
39	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. <i>PLoS ONE</i> , 2013 , 8, e67687	3.7	71
38	Non-AIDS-related Kaposi's sarcoma: A single-institution experience. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 52-7	2.5	8
37	Long lasting response to second-line everolimus in kidney cancer. <i>World Journal of Clinical Cases</i> , 2013 , 1, 166-8	1.6	
36	Capecitabine-gemcitabine in thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e18536-e18536	1.5	
35	Thymic epithelial tumors at University Federico II of Naples: A 30-year experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7603-7603	2.2	
34	Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma. <i>Anticancer Research</i> , 2013 , 33, 1135-9	2.3	5
33	Sipuleucel-T (Provenge [®]) for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110, E99-104	5.6	34
32	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 309-15	3.5	35
31	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
30	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. <i>Clinica Chimica Acta</i> , 2012 , 413, 1274-8	6.2	48
29	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. <i>Oncology Reports</i> , 2012 , 27, 409-15	3.5	13
28	How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 331-3	3.5	1
27	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1079-1080	4	2
26	Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2012 , 23, 573-7	2.4	26
25	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28

24	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. <i>World Journal of Clinical Oncology</i> , 2012 , 3, 111-5	2.5	9
23	Immunotherapy for the treatment of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 551-61	19.4	74
22	Neuroendocrine tumors diagnosed at the Antonio Cardarelli hospital (Naples, Italy) between 2006-2009: a single-institution analysis. <i>International Journal of Immunopathology and Pharmacology</i> , 2011 , 24, 251-6	3	1
21	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71
20	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
19	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , 2011 , 59, 526-40	20.2	89
18	Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. <i>European Urology</i> , 2011 , 60, 1280-4	10.2	48
17	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1455-61	3.5	22
16	Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 25-8	3.5	25
15	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 150-7	2.5	69
14	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1491-7	4	20
13	Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. <i>Oncology Letters</i> , 2011 , 2, 861-864	2.6	4
12	Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 377-83	2.5	31
11	A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 951-4	3	3
10	The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 1221-7	3	6
9	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	1000	77
8	The therapy of kidney cancer with biomolecular drugs. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S16-20	20.4	29
7	Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. <i>Anti-Cancer Drugs</i> , 2010 , 21, 465-8	2.4	4

6	Is hypogammaglobulinemia a constant feature in Good's syndrome?. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 1275-9	3	10
5	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 311-9	4.8	4
4	Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. <i>European Urology</i> , 2010 , 58, 636-7	10.2	22
3	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
2	Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2010 , 8, 8	3.4	2
1	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2526-30	5.6	25